205 / 260
The goodwill of
`
23.75 cr pertains to the control acquisition of Amal Ltd. The recoverable amount of the cash generating unit
has been determined based on the higher of fair value less costs of disposal and its value in use. The fair value less costs of
disposal has been determined based on closing quoted share price of Amal Ltd on an active market as on March 31, 2019.
During the year a subsidiary company acquired Active Pharma ingredients business of Polydrug Laboratories Pvt Ltd the
ĚNJČĚƙƙ ūlj ČūŠƙĿēĚƑîƥĿūŠ ƎîĿē ūDŽĚƑ ƥĺĚ ŠĚƥ îƙƙĚƥƙ îČƐƭĿƑĚē Džîƙ
`
8.56 cr and recognised as goodwill.
The Group has carried out impairment assessment as at March 31, 2019 for its all intangible assets. The Management believes
ƥĺîƥ îŠNj ƑĚîƙūŠîċŕNj ƎūƙƙĿċŕĚ ČĺîŠijĚ ĿŠ ƥĺĚ ŒĚNj îƙƙƭŞƎƥĿūŠƙ ŞîNj Šūƥ ČîƭƙĚ ƥĺĚ ČîƑƑNjĿŠij îŞūƭŠƥ ƥū ĚNJČĚĚē ƥĺĚ ƑĚČūDŽĚƑîċŕĚ
amount of the cash generating units. Accordingly, there was no impairment recorded during the year.
Note 5 Biological assets
a) Biological assets of the Group consists:
Ŀȴ
TŞŞîƥƭƑĚ ƥĿƙƙƭĚ ČƭŕƥƭƑĚ ƑîĿƙĚē ēîƥĚ ƎîŕŞƙ ƥĺîƥ îƑĚ ČŕîƙƙĿǛĚē îƙ ŠūŠȹČƭƑƑĚŠƥ ċĿūŕūijĿČîŕ îƙƙĚƥƙȦ ¹ĺĚ HƑūƭƎ ĺîƙ î
ƎƑūēƭČƥĿūŠ ČNjČŕĚ ūlj îċūƭƥ ljūƭƑȹǛDŽĚ NjĚîƑƙ
ĿĿȴ qîƥƭƑĚ ƥĿƙƙƭĚ ČƭŕƥƭƑĚ ƑîĿƙĚē ēîƥĚ ƎîŕŞƙ ƥĺîƥ îƑĚ ČŕîƙƙĿǛĚē îƙ ČƭƑƑĚŠƥ ċĿūŕūijĿČîŕ îƙƙĚƥƙȦ
b) Reconciliation of changes to the carrying value of biological assets between the beginning and the end of the current year
are as follows:
(
`
cr)
Particulars
Tissue culture raised date palms
March 31, 2019
March 31, 2018
Mature
Immature
Mature
Immature
Opening balance
11.20
11.50
11.77
9.32
Increase due to production
0.17
11.70
0.18
9.86
Change due to biological transformation
10.05
(10.05)
7.68
(7.68)
Decrease due to sale
ȳǧǩȦǪǨȴ
-
ȳǯȦǦǪȴ
-
Decrease due to write-off
(0.13)
-
(0.05)
-
Change in fair value due to price changes
1.16
-
0.66
-
Closing balance
9.03
13.15
11.20
11.50
Current assets
9.03
-
11.20
-
Non-current assets*
-
13.15
-
11.50
Biological assets shown in Balance Sheet
9.03
13.15
11.20
11.50
ȜsūŠȹČƭƑƑĚŠƥ ċĿūŕūijĿČîŕ îƙƙĚƥ Ŀƙ ĚNJƎĚČƥĚē ƥū ƥîŒĚ ŞūƑĚ ƥĺîŠ ǧǨ ŞūŠƥĺƙ ljƑūŞ ƑĚƎūƑƥĿŠij ēîƥĚ ƥū ċĚČūŞĚ ƑĚîēNj ljūƑ ēĿƙƎîƥČĺȦ
ƙ îƥ qîƑČĺ ǩǧȡ ǨǦǧǯ ƥĺĚ HƑūƭƎ ĺîē ǧǪȡǩǮǦ ŞîƥƭƑĚ ƎŕîŠƥƙ ȳqîƑČĺ ǩǧȡ ǨǦǧǮȠ ǭȡǯǩǪȴ îŠē ǩȡǪǨȡǭǧǬ ĿŞŞîƥƭƑĚ ƎŕîŠƥƙ ȳqîƑČĺ ǩǧȡ
ǨǦǧǮȠ ǪȡǧǪȡǪǩǬȴȦ
During current year the Group has sold 1,52,898 plants (March 31, 2018: 1,6
ǭȡǩǪǩȴȦ
(
`
cr)
Note 6.1 Investments accounted for using the
equity method
Place of
business
% of ownership
interest
As at
March 31, 2019
As at
March 31, 2018
Investment in equity instruments (fully paid-up)
ÀŠƐƭūƥĚē ĿŠDŽĚƙƥŞĚŠƥ ĿŠ ŏūĿŠƥ DŽĚŠƥƭƑĚ ČūŞƎîŠNjȠ
Rudolf Atul Chemicals Ltd
India
50
10.72
10.00
ēēȠ HƑūƭƎ ƙĺîƑĚ ūlj ƎƑūǛƥ ljūƑ ƥĺĚ NjĚîƑ
5.02
0.72
Total equity accounted investments
15.74
10.72
Consolidated
|
Notes to the Financial Statements
203